PORTFOLIO NEWS RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension June 18, 2019 Read More » Exonics Therapeutics Acquired by Vertex, Expanding into New Disease Areas and Enhances Gene Editing Capabilities June 6, 2019 Read More » Constellation’s Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients June 3, 2019 Read More » FLX Bio Announces Name Change to RAPT Therapeutics May 24, 2019 Read More » Peloton Therapeutics Acquired by Merck, Bolstering Oncology Pipeline May 21, 2019 Read More » ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer May 13, 2019 Read More » Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer May 2, 2019 Read More » Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock April 24, 2019 Read More » Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback April 22, 2019 Read More » Gritstone Oncology Announces Proposed Public Offering of Common Stock April 22, 2019 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
RAPT Therapeutics (Formerly FLX Bio) Completes $37 Million Series C Extension June 18, 2019 Read More »
Exonics Therapeutics Acquired by Vertex, Expanding into New Disease Areas and Enhances Gene Editing Capabilities June 6, 2019 Read More »
Constellation’s Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients June 3, 2019 Read More »
ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer May 13, 2019 Read More »
Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer May 2, 2019 Read More »
Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock April 24, 2019 Read More »
Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback April 22, 2019 Read More »
